ESBL-producing Escherichia coli in Swedish gulls-A case of environmental pollution from humans?

PloS One
Clara AtterbyJonas Bonnedahl

Abstract

ESBL-producing bacteria are present in wildlife and the environment might serve as a resistance reservoir. Wild gulls have been described as frequent carriers of ESBL-producing E. coli strains with genotypic characteristics similar to strains found in humans. Therefore, potential dissemination of antibiotic resistance genes and bacteria between the human population and wildlife need to be further investigated. Occurrence and characterization of ESBL-producing E. coli in Swedish wild gulls were assessed and compared to isolates from humans, livestock and surface water collected in the same country and similar time-period. Occurrence of ESBL-producing E. coli in Swedish gulls is about three times higher in gulls compared to Swedish community carriers (17% versus 5%) and the genetic characteristics of the ESBL-producing E. coli population in Swedish wild gulls and Swedish human are similar. ESBL-plasmids IncF- and IncI1-type carrying ESBL-genes blaCTX-M-15 or blaCTX-M-14 were most common in isolates from both gulls and humans, but there was limited evidence of clonal transmission. Isolates from Swedish surface water harbored similar genetic characteristics, which highlights surface waters as potential dissemination routes between ...Continue Reading

References

Apr 4, 2006·The Journal of Antimicrobial Chemotherapy·David SkurnikErick Denamur
Dec 14, 2007·The Journal of Antimicrobial Chemotherapy·Marie-Hélène Nicolas-ChanoineJames R Johnson
Dec 3, 2008·Applied and Environmental Microbiology·Nigel P FrenchPhilip Carter
Mar 2, 2010·Nature Reviews. Microbiology·Heather K AllenJo Handelsman
Jun 3, 2011·Journal of Clinical Microbiology·Silke PolsfussMichael Hombach
Dec 29, 2011·Frontiers in Microbiology·Sebastian GuentherLothar H Wieler
Feb 9, 2012·Antimicrobial Agents and Chemotherapy·Laurent PoirelL Silvia Munoz-Price
Apr 24, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C EwersL H Wieler
Jan 1, 2011·Infection Ecology & Epidemiology·Anders WallenstenBjörn Olsen
Nov 13, 2012·The Journal of Antimicrobial Chemotherapy·Marie-Hélène Nicolas-ChanoineVéronique Leflon-Guibout
Apr 16, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S BörjessonS Englund
Oct 5, 2013·Clinical Microbiology Reviews·Paul-Louis WoertherAntoine Andremont
Dec 4, 2013·Antimicrobial Agents and Chemotherapy·Giuseppe ValenzaChristiane Höller
Feb 20, 2014·The Journal of Antimicrobial Chemotherapy·Oskar NilssonBjörn Bengtsson
Apr 5, 2014·Upsala Journal of Medical Sciences·Jonas Bonnedahl, Josef D Järhult
Apr 23, 2014·Emerging Infectious Diseases·Jonas BonnedahlMirva Drobni
May 3, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Badrul HasanBjörn Olsen
May 20, 2014·Applied and Environmental Microbiology·Patrick S L KwanCollette Fitzgerald
Oct 11, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin LazarusBenjamin A Rogers
Oct 16, 2014·Infection Ecology & Epidemiology·Alma Brolund
Jul 3, 2015·Infectious Diseases·Alma Brolund, Linus Sandegren
Oct 17, 2015·The Journal of Antimicrobial Chemotherapy·Monika DolejskaIvan Literak
Oct 23, 2015·The Journal of Antimicrobial Chemotherapy·Paula GómezCarmen Torres
Nov 4, 2015·Acta Veterinaria Scandinavica·Johan StedtMirva Drobni
Feb 6, 2017·The Journal of Antimicrobial Chemotherapy·Sebastian GuentherKatharina Schaufler
Mar 18, 2017·Ecology and Evolution·Marion VittecoqFrançois Renaud

❮ Previous
Next ❯

Citations

Apr 4, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Huiyun ZouLennart E Nilsson
Jun 19, 2019·Antimicrobial Agents and Chemotherapy·Monika Dolejska, Ivan Literak
Mar 25, 2019·Journal of Environmental and Public Health·Hannah B HaberechtElizabeth P Ryan
Apr 10, 2019·BMC Biology·Vanessa R MarcelinoEdward C Holmes
May 14, 2020·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Anette M HammerumHenrik Hasman
Nov 26, 2020·Antibiotics·Karin SjöströmSusanna Sternberg Lewerin
Jul 3, 2021·Animals : an Open Access Journal From MDPI·Alejandro Suárez-PérezMaría Teresa Tejedor-Junco
Jul 31, 2021·Environmental Science and Pollution Research International·Murugadas VaiyapuriMukteswar Prasad Mothadaka
Aug 10, 2021·Frontiers in Microbiology·Danae Zeballos-GrossJulio A Benavides

❮ Previous
Next ❯

Software Mentioned

BioNumerics

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.